single cell-RNA sequencing for Immune cells from mouse brain tumor post anti PD-1 treatment
To evaluate the influence of ablating Fcgr2b on anti-PD-1 treatment efficacy, we administered GL261 cells to both Fcgr2b knockout and wild-type (WT) mice, followed by treatment with anti-PD-1. Afterwards, we isolated immune cells from the brains of these mice for further analysis. Overall design: We analyzed immune cells infiltrating gliomas using single-cell RNA sequencing (scRNAseq) with 10X Genomics technology. For the administration of anti-PD-1 immune checkpoint inhibitor (ICI), wild-type (WT) and Fcgr2b knockout (KO) mice received intraperitoneal injections of 200 µg of anti-mouse PD-1 depletion antibody on days 10, 13, and 16 after inoculation with 1x10^5 GL261 cells (Day 0). Tumor-bearing brains were isolated 20 days after tumor cell inoculation, and sorted CD45-positive immune cells were subsequently analyzed.